NeuroMetrix Rises 4%

NeuroMetrix shares advanced over 4% intraday after the company said Monday it received a patent that covers the application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation.

This core technology – U.S. Patent No. 9,656,070 – enables several advanced Quell features, including automatic adjustment of stimulation while the user is sleeping. Quell is the “only transcutaneous electrical nerve stimulator on the market” that can regulate neurostimulation and optimize relief from chronic pain, the company said in a statement. “With this patent, we have further strengthened our leadership position in wearable pain relief technology,” CEO Shai Gozani said.

By Jon Flanagan